Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
12.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Why Shares of Alvotech Jumped This Week
December 08, 2022
The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe.
Via
The Motley Fool
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 11, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
December 22, 2022
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 22, 2022
Via
Benzinga
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
December 22, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 22, 2022
Via
Benzinga
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
December 08, 2022
From
Alvotech
Via
GlobeNewswire
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
December 07, 2022
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...
Via
Benzinga
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
December 07, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Changes to its Leadership Team
December 01, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Secures Financing Facilities of Approximately $136 Million
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For November 15, 2022
November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.
Via
Benzinga
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
November 14, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
November 10, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
October 27, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
October 26, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
October 19, 2022
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.